Chardan Capital Reiterates Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has reiterated a Buy rating on Orchestra BioMed Holdings (NASDAQ:OBIO) and maintained a $20 price target.
June 12, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae has reiterated a Buy rating on Orchestra BioMed Holdings and maintained a $20 price target.
The reiteration of a Buy rating and a maintained price target of $20 by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100